Francois Cedric 4

What Happened Cedric Francois, CEO of Apellis Pharmaceuticals (APLS), transferred 64,869 shares on March 11, 2026. The Form 4 shows the transaction coded as a gift (G) at $0.00 — a disposal by the reporting person and an acquisition by the named trust — so the reported dollar value is $0.

Key Details

• Transaction date: 2026-03-11; Form 4 filed: 2026-03-13 (appears timely, within the standard 2-business-day window).
• Shares transferred: 64,869; price per share: $0.00; total reported value: $0.
• Post-transaction ownership: The filing indicates the shares are held by The Cedric Francois Irrevocable Trust of 2023 - 2 and that Cedric Francois disclaims beneficial ownership of those shares except to the extent of any pecuniary interest; the excerpt does not list a remaining personal share total.
• Notable footnotes: F1 states the transfer to The Cedric Francois Irrevocable Trust of 2023 - 2 (trustee Patrick Collins) and the disclaimer of beneficial ownership. Additional footnotes (F2–F4) note other trusts (with named trustees) that hold Apellis shares for which the reporting person similarly disclaims beneficial ownership.
• Transaction type: Gift (G). No sale, purchase, option exercise, or cash proceeds reported.

Context Gifts to trusts are commonly used for estate or tax planning and do not necessarily reflect an insider’s view on the company’s stock. For retail investors, purchases typically convey more direct insider confidence; this filing documents an internal transfer to a trust rather than a market sale or buy. For full holdings and any related disclosures, consult the complete Form 4 filing (Accession 0001193125-26-106090).